Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 46065. Отображено 100.
05-01-2012 дата публикации

Use Of Serine Protease Inhibitors In The Treatment Of Neutropenia

Номер: US20120004395A1
Автор: Adriano Fontana, Christoph Kundig, Mike Recher
Принадлежит: MED DISCOVERY SA, Universitaet Zuerich

The invention relates to therapeutic compounds which are inhibitors of serine proteases, to pharmaceutical compositions thereof and to their use in the treatment of the human or animal body. More specifically, the present invention relates to a method for the treatment of neutropenia comprising the administration to a subject in need thereof of a therapeutically effective amount of a serine protease inhibitor. The invention also comprises prevention of apoptosis of myeloid cells (1) during and after transfection of bone marrow cells performed for gene therapy, (2) during blood stem cell mobilization performed for reconstitution of hematopoiesis and (3) during infusion of cells of the myeloid lineage for reconstitution of hematopoiesis for gene therapy or for treatment of neutropenia by infusion of neutrophils.

Подробнее
Номер записи: 1
12-01-2012 дата публикации

Biomarkers for myocardial ischemia

Номер: US20120009174A1
Автор: Jennifer Van Eyk, QIN Fu, Simon Sheng
Принадлежит: JOHNS HOPKINS UNIVERSITY

This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention.

Подробнее
Номер записи: 2
12-01-2012 дата публикации

Modified Fc Molecules

Номер: US20120009205A1
Автор: Colin V. Gegg, Fei Xiong, Kenneth W. Walker, Leslie P. Miranda
Принадлежит: AMGEN INC

Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

Подробнее
Номер записи: 3
12-01-2012 дата публикации

Use of Molecular Chaperones for the Enhanced Production of Secreted, Recombinant Proteins in Mammalian Cells

Номер: US20120009670A1
Автор: Hsinyi Yvette Tang, Ruth Kelly, Sham-Yuen Chan, Yiwen Tao, Yongjian Wu
Принадлежит: Bayer Pharmaceuticals Corp

The present invention relates to a method for increased production of a secreted, recombinant protein product through the introduction of molecular chaperones in a mammalian host cell. The present invention also relates to a mammalian host cell with enhanced expression of a secreted recombinant protein product by coexpressing at least one chaperone protein.

Подробнее
Номер записи: 4
12-01-2012 дата публикации

Drug Delivery System for Use in the Treatment of Vascular and Vessel-Related Pathologies

Номер: US20120010557A1
Автор: Michal Heger
Принадлежит: ACADEMISCH MEDISCH CENTRUM

The present invention relates to a drug delivery system for use in the treatment of vascular and vessel-related pathologies, comprising a drug delivery platform that comprises at least one compound capable of exerting an effect on the formation and/or maintenance of a thrombus in the vessel to be treated. The platform is preferably formed by liposomes that are sterically stabilized by grafting of poly(ethylene glycol) onto the liposome surface. The liposomes may further comprise photosensitizers and targeting molecules. The liposomes may be thermosensitive. The compound is suitably tranexamic acid. The drug delivery system is preferably used for the treatment of port wine stains.

Подробнее
Номер записи: 5
19-01-2012 дата публикации

Kallikrein-inhibitor therapies

Номер: US20120015881A1
Автор: Anthony Williams, Arthur C. Ley, Luigi Bergamaschini, Maria Grazia De Simoni, Robert C. Ladner, Shirish Hirani
Принадлежит: Dyax Corp

Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.

Подробнее
Номер записи: 6
26-01-2012 дата публикации

Recombinant FcRn and Variants Thereof for Purification of Fc-Containing Fusion Proteins

Номер: US20120021484A1
Автор: Kevin A. McDonnell
Принадлежит: BIOGEN IDEC MA INC

The invention is directed to methods of purifying Fc-containing molecules using a soluble neonatal Fc receptor (sFcRn). Native FcRn binds Fc-containing proteins at or below about pH 6.5 and releases them at or above about pH 7 and provides a much milder approach for capturing and purifying Fc-containing proteins, in particular, therapeutic Fc-containing proteins. Other embodiments of the invention provide modifications to alter the pH for binding and elution to the sFcRn, to modulate Fc-containing protein binding affinity, to affect sFcRn linkage to a support surface, or to improve the stability of sFcRn to conditions utilized in the methods of the invention.

Подробнее
Номер записи: 7
26-01-2012 дата публикации

Genetic markers for risk management of atrial fibrillation and stroke

Номер: US20120021989A1
Автор: Daniel Gudbjartsson, Hilma Holm
Принадлежит: DECODE GENETICS EHF

The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic 5 methods, uses and procedures for utilizing such susceptibility markers.

Подробнее
Номер записи: 8
02-02-2012 дата публикации

Methods for dewatering wet algal cell cultures

Номер: US20120024797A1
Автор: Aniket Kale
Принадлежит: Individual

A method of dewatering algae and recycling water therefrom is presented. A method of dewatering a wet algal cell culture includes removing liquid from an algal cell culture to obtain a wet algal biomass having a lower liquid content than the algal cell culture. At least a portion of the liquid removed from the algal cell culture is recycled for use in a different algal cell culture. The method includes adding a water miscible solvent set to the wet algal biomass and waiting an amount of time to permit algal cells of the algal biomass to gather and isolating at least a portion of the gathered algal cells from at least a portion of the solvent set and liquid of the wet algal biomass so that a dewatered algal biomass is generated. The dewatered algal biomass can be used to generated algal products such as biofuels and nutraceuticals.

Подробнее
Номер записи: 9
02-02-2012 дата публикации

Spray-Dried Blood Products and Methods of Making Same

Номер: US20120027867A1
Автор: Joseph A. Dacorta, Michael Lawrence Galiger, Thomas H. Fischer
Принадлежит: Entegrion Inc

The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.

Подробнее
Номер записи: 10
02-02-2012 дата публикации

Highly sensitive detection method for highly virulent oral cavity bacteria

Номер: US20120028879A1
Автор: Kazuhiko Nakano, Kazuo Umemura, Kazuya Hokamura, Koichiro Wada, Ryota Nomura, Takashi Ooshima
Принадлежит: Hamamatsu University School of Medicine NUC

Provided is a method that involves the detection of protein antigen (PA) and/or collagen-binding protein (CBP) of oral cavity bacteria in a sample, and in which oral cavity bacteria that exacerbate hemolysis are detected for and/or subjects at high-risk for hemolysis aggravation are screened anchor the level of risk of the hemolysis aggravation in a subject is assessed if a PA is not detected anchor a CBP is detected in the sample. Also provided are a detection reagent and kit for use in the method.

Подробнее
Номер записи: 11
02-02-2012 дата публикации

Novel Crystalline Form of Atorvastatin Hemi-calcium Salt, Hydrate Thereof, And Method of Producing The Same

Номер: US20120029207A1
Автор: Do Yeon Oh, Doo Seong Choi, Hoe Joo Son, Kyung Ju Lee, Sun Ho Chang
Принадлежит: KYONGBO PHARM

The present invention provides a novel crystalline form of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-mthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptanoic acid hemi-calcium salt (atorvastatin hemi-calcium salt) of the following formula 1, which is known to be useful as a drug, a hydrate thereof and a preparation method thereof:

Подробнее
Номер записи: 12
09-02-2012 дата публикации

Neuronal differentiation-inducing peptide and use thereof

Номер: US20120035112A1
Автор: Nahoko Kobayashi, Tetsuhiko Yoshida
Принадлежит: TOAGOSEI CO LTD

A neuronal differentiation inducer provided by the present invention contains an artificially synthesized peptide which includes an amino acid sequence constituting a signal peptide in amyloid precursor protein (APP), or a partial sequence of the amino acid sequence constituting this signal peptide.

Подробнее
Номер записи: 13
09-02-2012 дата публикации

Substituted dihydropyrazolones and their use

Номер: US20120035151A1
Автор: Friederike Stoll, Hartmut Beck, Ingo Flamme, Mario Jeske, Metin Akbaba
Принадлежит: Bayer Pharma AG

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.

Подробнее
Номер записи: 14
09-02-2012 дата публикации

Selective extraction of proteins from freshwater algae

Номер: US20120035348A1
Автор: Aniket Kale
Принадлежит: Heliae Development LLC

Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.

Подробнее
Номер записи: 15
23-02-2012 дата публикации

Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF

Номер: US20120042613A1
Автор: Helmut Lerch, Klaus Graumann, Thomas Lauber
Принадлежит: SANDOZ AG

The present invention provides a method for stable long-term storage of non-glycosylated recombinant human G-CSF, wherein an aqueous acetate or glutamate buffered G-CSF composition containing non-glycosylated recombinant human G-CSF and sorbitol is cooled to a temperature of −15° C. or below to obtain a frozen G-CSF composition, which frozen composition is then stored in the frozen state. The temperature of the frozen G-CSF composition is later increased to a temperature within the range of from 2° C. to 8° C. for a time selected to allow the G-CSF composition to thaw and to obtain a liquid G-CSF composition having a G-CSF content of at least 95% of the G-CSF content of the original composition.

Подробнее
Номер записи: 16
23-02-2012 дата публикации

Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation

Номер: US20120046235A9
Автор: Nobert Zander, Ronald Frank
Принадлежит: Individual

Conjugates of an active substance and hydroxyalkyl starch (HAS) are provided herein. The active substance and the HAS are linked by a chemical moiety having a structure according to formula (I) wherein Y is O or S, and X is SH or (F). The conjugate has a structure according to formula (IV) wherein HAS′ is a residue of HAS or a derivative thereof linked to the thioester group, and AS′ is a residue of the active substance or derivative thereof linked to the alpha-X beta-amino group; or a structure according to formula (V) wherein HAS′ is a residue of HAS or derivative thereof linked to the alpha-X beta-amino group, and AS′ is a residue of the active substance or derivative thereof linked to the thioester group, and wherein the group —(C═Y) is derived from the thioester group —(C═Y)—S—R′ and the group HN—CH—CH 2 —X is derived from the alpha-X beta amino group.

Подробнее
Номер записи: 17
23-02-2012 дата публикации

Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family

Номер: US20120046345A1
Автор: Joseph Collard, Olga Khorkova Sherman
Принадлежит: OPKO CURNA LLC

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of Dystrophin family. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DMD family.

Подробнее
Номер записи: 18
08-03-2012 дата публикации

Carbazole and carboline kinase inhibitors

Номер: US20120058988A1
Автор: Ashok Vinayak Purandare, Douglas G. Batt, Harold Mastalerz, Kurt Zimmermann, Qingjie Liu
Принадлежит: Bristol Myers Squibb Co

The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof The Formula (I) compounds inhibit tyrosine kinase activity of Jak2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Подробнее
Номер записи: 19
08-03-2012 дата публикации

Method for reducing thrombocytopenia and thrombocytopenia-associated mortality

Номер: US20120059036A1
Автор: Marco Valgimigli
Принадлежит: Individual

Disclosed are methods for reducing the risk of thrombocytopenia-associated mortality and morbidity, and for reducing the risk of becoming thrombocytopenic, in patients whose treatment requires inhibition of platelet aggregation. The methods involve administration of a pharmaceutically acceptable salt of tirofiban.

Подробнее
Номер записи: 20
15-03-2012 дата публикации

Isotopologues of thalidomide

Номер: US20120064004A1
Автор: George W. Muller, Hon-Wah Man
Принадлежит: Celgene Corp

Provided herein are thalidomide, which is enriched with isotopes such as deuterium. Pharmaceutical compositions comprising the isotopes-enriched compounds, and methods of using such compounds are also provided.

Подробнее
Номер записи: 21
15-03-2012 дата публикации

Aminoacyl trna synthetases for modulating hematopoiesis

Номер: US20120064082A1
Автор: Alain P. Vasserot, Jeffry Dean Watkins, Leslie Ann Greene, Rajesh Belani, Ryan Andrew Adams
Принадлежит: aTyr Pharma Inc

Hematopoietic-modulating compositions are provided comprising aminoacyl-tRNA synthetase polypeptides, including active fragments and/or variants thereof, as well as compositions comprising related agents such as antibodies and other binding agents. Also provided are methods of using such compositions in the treatment of conditions that benefit from the modulation of hematopoiesis.

Подробнее
Номер записи: 22
15-03-2012 дата публикации

Recombinant factor viii having enhanced stability following mutation at the a1-c2 domain interface

Номер: US20120065136A1
Автор: Hironao Wakabayashi, Philip J. Fay
Принадлежит: UNIVERSITY OF ROCHESTER

The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.

Подробнее
Номер записи: 23
15-03-2012 дата публикации

Identification of a jak2 mutation involved in vaquez polyglobulia

Номер: US20120066776A1
Автор: Chloe James, Jean-Pierre Le Couedic, Nicole Casadevall, Valerie Ugo, William Vainchenker
Принадлежит: Assistance Publique Hopitaux de Paris APHP, IGR&D SA, Institut National de la Sante et de la Recherche Medicale INSERM

The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Подробнее
Номер записи: 24
22-03-2012 дата публикации

Method For Enucleating Nucleated Erythrocyte, And Enucleation Inducer

Номер: US20120070897A1
Автор: Eriko Shimamura, Hiroki Shimada, Toshihisa Hatta
Принадлежит: KANAZAWA MEDICAL UNIVERSITY

Provided is a factor capable of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time. More particularly, provided are a method of inducing enucleation, which is a final stage of erythrocyte differentiation, within a short time by adding a compound derived from proopiomelanocortin (POMC) to an undifferentiated (nucleated) erythrocyte, and an enucleation inducer including the compound.

Подробнее
Номер записи: 25
22-03-2012 дата публикации

Modified vegf-a with improved angiogenic properties

Номер: US20120071406A1
Автор: Kari Alitalo, Katri Pajusola, Markku M. Jeltsch, Marko J. T. Uutela, Salla Keskitalo, Seppo Yla-Herttuala, Terhi Karpanen, Tuomas Tammela, Ulf Eriksson
Принадлежит: Vegenics Pty Ltd

The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-2 ligand. The chimeric molecules of the present invention retain VEGFR-2 binding activity and an enhanced angiogenic activity as compared to native VEGF-A.

Подробнее
Номер записи: 26
22-03-2012 дата публикации

Prevention and treatment of blood coagulation-related disases

Номер: US20120073002A1
Автор: Hiroyuki Saito, Kazutaka Yoshihashi, Kunihiro Hattori, Takehisa Kitazawa
Принадлежит: Chugai Pharmaceutical Co Ltd

Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.

Подробнее
Номер записи: 27
29-03-2012 дата публикации

Antagonists of pcsk9

Номер: US20120076799A1
Автор: Ayesha Sitlani, Carl P. Sparrow, Holly A. Hammond, Jon H. Condra, Shilpa Pandit
Принадлежит: Merck Sharp and Dohme LLC

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Подробнее
Номер записи: 28
29-03-2012 дата публикации

Antibodies to troponin i and methods of use thereof

Номер: US20120076803A1
Автор: Bailin Tu, Dagang Huang, Joan D. Tyner, Lowell J. Tyner, Robert N. Ziemann, Susan E. Brophy
Принадлежит: ABBOTT LABORATORIES

The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.

Подробнее
Номер записи: 29
29-03-2012 дата публикации

Steroid-sparing methods of treating brain edema

Номер: US20120077744A1
Автор: Lisa Carr, Stephen Evans-Freke
Принадлежит: Neutron Ltd

The present invention relates to therapeutic regimens or protocols designed for the treatment, management or prevention of edema. In particular, the invention pertains to methods of treating or managing edema associated with brain tumors involving the administration of a therapeutically effective amount of corticorelin acetate that achieves a steroid-sparing effect.

Подробнее
Номер записи: 30
29-03-2012 дата публикации

Remotely imageable marker system and polysaccharide marker for use in same

Номер: US20120078092A1
Автор: Michael L. Jones, Paul Lubock
Принадлежит: SenoRx Inc

A remotely imageable marker system includes a tubular delivery member having an inner lumen and a plurality of marker members. Each marker member of the plurality of marker members comprises a bioabsorbable polysaccharide in sufficient amount to exhibit hemostatic properties and a binder. The plurality of marker members is disposed within the inner lumen of the tubular delivery member.

Подробнее
Номер записи: 31
05-04-2012 дата публикации

Methods for preventing and treating angioedema

Номер: US20120082676A1
Автор: Berhane Ghebrehiwet
Принадлежит: Research Foundation of State University of New York

One aspect of the present invention provides a method of treating or preventing angioedema in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R. One aspect of the present invention provides a method of treating or preventing vascular permeability in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that is capable of inhibiting the interaction of HK with gC1q-R.

Подробнее
Номер записи: 32
05-04-2012 дата публикации

Antagonists of pcsk9

Номер: US20120082680A1
Автор: Ayesha Sitlani, Carl P. Sparrow, Dana D. Wood, Jon H. Condra, Shilpa Pandit, Timothy S. Fisher
Принадлежит: Merck Sharp and Dohme LLC

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Подробнее
Номер записи: 33
05-04-2012 дата публикации

Novel albumin-free factor viii formulations

Номер: US20120083446A1
Автор: Erik Bjornson, Feroz Jameel, John Carpenter, Marc Besman, Michael Pikal, Ramesh Kashi, Serguei Tchessalov
Принадлежит: Baxter International Inc, University of Connecticut

An albumin-free Factor VIII formulation comprising, 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent.

Подробнее
Номер записи: 34
19-04-2012 дата публикации

Human artificial chromosome (hac) vector

Номер: US20120093785A1
Автор: Kazuma Tomizuka, Minoru Kakeda, Mitsuo Oshimura, Motonobu Katoh, Yoshimi Kuroiwa
Принадлежит: Kirin Brewery Co Ltd

The present invention relates to a human artificial chromosome (HAC) vector and a method for producing the same. The present invention further relates to a method for introducing foreign DNA using a human artificial chromosome vector and a method for producing a cell which expresses foreign DNA. Furthermore, the present invention relates to a method for producing a protein.

Подробнее
Номер записи: 35
19-04-2012 дата публикации

Methods of treating hypertriglyceridemia

Номер: US20120093924A1
Автор: Ian OSTERLOH, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharma Inc

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Подробнее
Номер записи: 36
26-04-2012 дата публикации

Anti-ferroportin 1 monoclonal antibodies and uses thereof

Номер: US20120100148A9
Автор: Derrick Ryan Witcher, Donmienne Doen Mun Leung, Joseph Vincent Manetta, Peng Luan, Ying Tang
Принадлежит: Eli Lilly and Co

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a subject in vivo.

Подробнее
Номер записи: 37
26-04-2012 дата публикации

Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof

Номер: US20120101029A1
Автор: Asya Varshavsky, Boaz Kigel, Gera Neufeld, Ofra Kessler
Принадлежит: Rappaport Family Institute for Research in the Medical Sciences

A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.

Подробнее
Номер записи: 38
26-04-2012 дата публикации

Method for screening inhibitor for inhibiting interaction between beta-amyloid peptide and vegf and inhibitor searched by the same

Номер: US20120101284A1
Автор: Chan-Won Park, In-Cheol Kang
Принадлежит: Innopharmascreen Inc

There is provided a compound found by screening a material for inhibiting a binding between a beta-amyloid 1-42 peptide and VEGF165, in which the inhibition material screened according to the present invention can improve effectiveness as a material for treating Alzheimer's disease.

Подробнее
Номер записи: 39
03-05-2012 дата публикации

Method of Inhibiting Smooth Muscle Cell Proliferation by Using Reconstituted HDL

Номер: US20120108495A1
Автор: Bok Soo Lee, Jeong Euy Park, Ki Yong Kim
Принадлежит: Green Cross Corp Korea, SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

A method of inhibiting smooth muscle cell proliferation comprising administering to a subject a pharmaceutical composition including reconstituted HDL as an active ingredient.

Подробнее
Номер записи: 40
03-05-2012 дата публикации

Fused piperidine compound and pharmaceutical containing same

Номер: US20120108581A1
Автор: Hajime Yamada, Hiroyuki Ishiwata, Masanori Ashikawa, Shunji Takemura, Takeshi Doi, Tatsuaki Nishiyama, Toshiharu Morimoto
Принадлежит: Kowa Co Ltd

The present invention provides a low molecular weight compound having EPO production-promoting action and/or hemoglobin production-promoting action. The present invention relates to a fused piperidine compound represented by the following general formula (1): (wherein, ring A represents a C 10-14 aryl group or 5- to 10-membered heterocyclic group, X represents N—R 7 , a sulfur atom or an oxygen atom, R 1 , R 2 , R 2′ , R 3 and R 3′ independently represent a hydrogen atom, C 1-6 alkyl group or C 3-6 cycloalkyl group, and R 4 , R 5 and R 6 independently represent a hydrogen atom or halogen atom), or a salt thereof, or a solvate thereof.

Подробнее
Номер записи: 41
10-05-2012 дата публикации

Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders

Номер: US20120115831A1
Автор: Richard Hausknecht
Принадлежит: Individual

The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective dosages and lengths of treatment that are lower and/or shorter than previously thought possible.

Подробнее
Номер записи: 42
10-05-2012 дата публикации

Compositions and their uses directed to hepcidin

Номер: US20120115930A1
Автор: Brett P. Monia, C. Frank Bennett, Robert Mckay, Trisha Lockhart, William A. Gaarde
Принадлежит: ISIS PHARMACEUTICALS INC

Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.

Подробнее
Номер записи: 43
17-05-2012 дата публикации

Protein conjugate having an endopeptidase- cleavable bioprotective moiety

Номер: US20120121613A1
Автор: Baisong Mei, John E. Murphy, Jun Wang, Liang Tang
Принадлежит: Bayer HealthCare LLC

The invention is directed to a procoagulant conjugate having an endopeptidase-activatable procoagulant protein moiety and one or more bioprotective moieties, which are conjugated to one another by a linker that is cleaved by an endopeptidase in situ to release the bioprotective moiety. The invention is also directed to therapeutic uses of the procoagulant conjugate and methods of making the conjugate.

Подробнее
Номер записи: 44
17-05-2012 дата публикации

Peptide

Номер: US20120121625A1
Автор: David Wraith
Принадлежит: Apitope Technology Bristol Ltd

The present invention provides peptides at least partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides a peptide comprising or consisting of the sequence EDNIMVTFRNQASR. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia.

Подробнее
Номер записи: 45
17-05-2012 дата публикации

Water soluble defructosylated pea extract, and use thereof as a prebiotic agent

Номер: US20120121741A1
Автор: Francois Delbaere
Принадлежит: DELBAERE Francois

The present invention relates to a water-soluble defructosylated pea extract, substantially free of proteins and peptides, as well as to an oligosaccharide composition such as that contained in said extract. It also relates to the method for preparing the same, and to the use thereof as a prebiotic agent.

Подробнее
Номер записи: 46
17-05-2012 дата публикации

Libraries of n-substituted-n-phenylethylsulfonamides for drug discovery

Номер: US20120122920A1
Автор: David Enrique MIGUEL CENTENO, Josep Castells Boliart, Marta Pascual Gilabert
Принадлежит: Institut Universitari de Ciencia i Tecnologia

New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to N-substituted-N-phenylethylsulfonamides libraries which can be used in the search for, and identification of, new lead compounds that could modulate the functional activity of a biological target.

Подробнее
Номер записи: 47
17-05-2012 дата публикации

Novel crystalline form of atorvastatin hemi-calcium salt, hydrate thereof, and method of producing the same

Номер: US20120123132A1
Автор: Do Yeon Oh, Doo Seong Choi, Hoe Joo Son, Kyung Ju Lee, Sun Ho Chang
Принадлежит: KYONGBO PHARM

The present invention provides a novel crystalline form of [R-(R * ,R * )]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-mthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptanoic acid hemi-calcium salt (atorvastatin hemi-calcium salt) of the following formula 1, which is known to be useful as a drug, a hydrate thereof and a preparation method thereof:

Подробнее
Номер записи: 48
24-05-2012 дата публикации

Synthetic macrocyclic compounds and methods for treating cancer

Номер: US20120128657A1
Автор: Belhu B. Metaferia, Carole A. Bewley, Xin-Yu Huang
Принадлежит: CORNELL UNIVERSITY, US Department of Health and Human Services

Disclosed herein are macrocyclic compounds that are effective to inhibit cell migration. In one embodiment, the compounds have the structure: or any pharmaceutically acceptable salt or solvate thereof, wherein: m is 0 or 1; R 1 , R 2 and R 3 independently are H, aralkyl, acyl, lower alkyl or silyl; X is —C(O)N(R 4 )— or —C(S)N(R 4 )—; —C(O)—; —C(S)—; Y is —OC(O)—; —OC(O)N(R 5 )—; —N(R 5 )C(O)—; or —OC(O)O—; G comprises a saturated or unsaturated aliphatic chain having from 2 to about 10 atoms in the chain, the chain optionally including 1, 2, or 3 heteroatoms; the chain optionally being substituted with 1, 2 or 3 substituents independently selected from lower alkyl, —OR 6 , epoxy, aziridinyl, cyclopropyl, —NR 7 R 8 and halo; R 4 , R 5 , R 6 , R 7 and R 8 independently are selected from H, lower alkyl and acyl. Also disclosed are methods for making and using compounds as well as pharmaceutical compositions including one or more of the disclosed macrocycles.

Подробнее
Номер записи: 49
24-05-2012 дата публикации

Truncated cd20 protein, deltacd20

Номер: US20120129167A1
Автор: Carole Henry, Christophe Borg, Christophe Ferrand, Marina Deschamps, Pierre Tiberghien, Pierre-Simon Rohrlich
Принадлежит: Francais du Sang Ets

The present invention relates in particular to a protein from an alternative splicing of the gene encoding CD20, the nucleic acid sequences encoding the protein according to the invention, a mutated form of the CD20 gene as well as drugs, diagnostic tools, diagnostic methods and treatment methods using the protein and the nucleic acid sequences according to the invention.

Подробнее
Номер записи: 50
24-05-2012 дата публикации

Inhibition of ApoE Cleavage Activity in the Treatment of ApoE-Related Disorders

Номер: US20120129782A1
Автор: Karl H. Weisgraber, Mei Xiu Steele, QIN Xu, Robert W. Mahley, Stephen Barry Freedman, Yadong Huang
Принадлежит: J David Gladstone Institutes

The present invention provides methods for treating apoE-related disorders. The methods generally involve administering an effective amount of an agent that inhibits activity of an enzyme that cleaves apoE.

Подробнее
Номер записи: 51
07-06-2012 дата публикации

Heteroalkyl linked pyrimidine derivatives

Номер: US20120142680A1
Автор: Anders Poulsen, Anthony Deodaunia William, Cheng Hsia Angeline Lee, Ee Ling Teo, Eric T. Sun, Harish Kumar Mysore Nagaraj, Kantharaj Ethirajulu, Stéphanie Blanchard, Yee Ling Evelyn Tan
Принадлежит: SBio Pte Ltd

The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to heteroalkyl linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other conditions or disorders associated with kinases.

Подробнее
Номер записи: 52
14-06-2012 дата публикации

Use of Inclusion Bodies as Therapeutic Agents

Номер: US20120148529A1
Автор: Antonio Pedro Villa Verde Corrales, Elena Garcia-Fruitos, Esther Vázquez Gómez, Jose Luis Corchero
Принадлежит: Centro de Investigacion Biomedica en Red en Bioingenieria Biomateriales y Nanomedicina CIBERBBN, Universitat Autonoma de Barcelona UAB

The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by therapeutic proteins. These inclusion bodies formed by therapeutic proteins could be used for the treatment of different diseases.

Подробнее
Номер записи: 53
21-06-2012 дата публикации

Targeting agent to newly formed blood vessels

Номер: US20120156132A1
Автор: Kentaro Nakamura, Yasuhiko Tabata
Принадлежит: Fujifilm Corp, KYOTO UNIVERSITY

It is an object of the present invention to provide a targeting agent that enables drug delivery to a neovascular site and the imaging of such a neovascular site, utilizing the effect of the agent to accumulate in the neovascular site. The present invention provides a targeting agent to a neovascular site, which comprises a gelatin-like protein.

Подробнее
Номер записи: 54
21-06-2012 дата публикации

Biodegradable Osmotic Pump Implant For Drug Delivery

Номер: US20120156289A1
Автор: Phillip Blaskovich, Rachit Ohri, Steven Bennett
Принадлежит: Confluent Surgical Inc

The present disclosure relates to a drug delivery device including a biodegradable housing and a hydrogel within the biodegradable housing. The housing, the hydrogel, or both, may include a bioactive agent. Also disclosed is a method of drug delivery including the steps of forming the biodegradable housing, in embodiments a hydrogel, suspending a bioactive agent in the hydrogel, and introducing a second hydrogel and/or precursors of a second hydrogel into the biodegradable housing.

Подробнее
Номер записи: 55
21-06-2012 дата публикации

Cyclosporin conjugates

Номер: US20120157385A1
Автор: David Selwood, Martin Crompton
Принадлежит: UCL BUSINESS LTD

A conjugate which comprises a cyclosporin moiety of formula (I) linked to one or more mitochondrial targeting groups, or a pharmaceutically acceptable salt thereof: wherein: A represents or, B represents methyl or ethyl, one Of R 1 and R 1 represents hydrogen and the other represents methyl, R 2 represents ethyl or isopropyl, R 3 represents hydrogen or methyl, and R 4 represents —CH 2 CH(CH 3 )CH 3 , —CH 2 CH(CH 3 )CH 2 CH 3 , —CH(CH 3 )CH 3 or —CH(CH 3 )CH 2 CH 3 .

Подробнее
Номер записи: 56
21-06-2012 дата публикации

Methods of treating hypertriglyceridemia

Номер: US20120157530A1
Автор: Ian OSTERLOH, Mehar Manku, Paresh Soni, Pierre Wicker, Rene Braeckman
Принадлежит: Amarin Pharma Inc

In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Подробнее
Номер записи: 57
28-06-2012 дата публикации

Temperature sensitive hydrogel and block copolymers

Номер: US20120164100A1
Автор: Faquan Zeng, Ren-Ke Li
Принадлежит: UNIVERSITY HEALTH NETWORK

The present disclosure provides temperature sensitive hydrogels and block copolymers, processes for the production thereof, and therapeutic and research compositions employing these copolymers.

Подробнее
Номер записи: 58
28-06-2012 дата публикации

Nitrogen-Based Linkers for Attaching Modifying Groups to Polypeptides and Other Macromolecules

Номер: US20120165275A1
Автор: Anjan Chakrabarti, Ashok Bhandari, Brian T. Frederick, Christopher P. Holmes, Yaohua S. Dong, Yijun Pan
Принадлежит: Affymax Inc

Compounds comprising a peptide moiety, a linker moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety are disclosed. Various linker moieties for use in these compounds are also disclosed, along methods for their synthesis.

Подробнее
Номер записи: 59
05-07-2012 дата публикации

method for producing a nutraceutical composition and the nutraceutical produced by the method

Номер: US20120171186A1
Автор: Woon San Liang
Принадлежит: Individual

A method for producing a nutraceutical composition comprising a combination of oil soluble antioxidants derived from an edible oil and water soluble antioxidants derived from a plant extract, wherein the plant extract further provides a natural surfactant; and the nutraceutical composition produced by that method.

Подробнее
Номер записи: 60
05-07-2012 дата публикации

Hsp90 inhibitors

Номер: US20120172321A1
Автор: Erick Co, Huong-Thu Ton-Nu, Jeffrey A. Stafford, John D. Lawson, Prasuna Guntupalli, Wolfgang Reinhard Ludwig Notz, Young K. Chen
Принадлежит: Takeda Pharmaceutical Co Ltd

The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Подробнее
Номер записи: 61
12-07-2012 дата публикации

Vegf antagonist formulations

Номер: US20120178683A1
Автор: Daniel Dix, Kelly Frye, Susan Kautz
Принадлежит: Regeneron Pharmaceuticals Inc

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.

Подробнее
Номер записи: 62
12-07-2012 дата публикации

Cofactors for Thrombin Activation of Factor VII and Uses Thereof

Номер: US20120178693A1
Автор: David Kiewlich, David Light, Maxine Bauzon, Terry Hermiston
Принадлежит: Bayer HealthCare LLC

The invention relates to fusion proteins that bind the enzyme thrombin and enhance the activation of the substrate Factor VII to the product Factor VIIa. The invention is also directed to polynucleotides, vectors, host cells, pharmaceutical compositions, and methods of treatment.

Подробнее
Номер записи: 63
26-07-2012 дата публикации

Angiogenesis inhibitors

Номер: US20120190659A1
Автор: Akiko Mammoto, Barbara Czako, Donald E. Ingber, Elias James Corey, László KÜRTI
Принадлежит: Childrens Medical Center Corp, Harvard College

Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis:

Подробнее
Номер записи: 64
26-07-2012 дата публикации

Lenalidomide salts

Номер: US20120190711A1
Автор: Jacobus Theodorus Henricus Van Eupen
Принадлежит: Synthon BV

The present invention relates to acid addition salts of lenalidomide, wherein said acid has a pKa lower than 1, preferably selected from hydrochloric acid, hydrobromic acid, methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid and p-toluenesulfonic acid, to processes for their making, and use in medicine, and to purification of lenalidomide base.

Подробнее
Номер записи: 65
26-07-2012 дата публикации

Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses

Номер: US20120190827A1
Автор: Anna-Maria A. HAYS PUTNAM, Denise Krawitz, Feng Tian, Ho Sung Cho, Joseph Sheffer, Richard D. Dimarchi, Stephanie Chu, Thea Norman
Принадлежит: Ambrx Inc

Modified human plasma polypeptides or Fc and uses thereof are provided.

Подробнее
Номер записи: 66
02-08-2012 дата публикации

Anti-pcsk9 antibodies and methods of use

Номер: US20120195910A1
Автор: Andrew Peterson, Cecilia Chiu, Daniel Kirchhofer, Ganesh Kolumam, Monica KONG BELTRAN, Paul Moran, Wei Li, Yan Wu
Принадлежит: Genentech Inc

The invention provides anti-PCSK9 antibodies and methods of using the same.

Подробнее
Номер записи: 67
02-08-2012 дата публикации

Therapeutic Inhibitor of Vascular Smooth Muscle Cells

Номер: US20120195951A1
Автор: Lawrence L. Kunz, Peter G. Anderson
Принадлежит: Individual

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

Подробнее
Номер записи: 68
02-08-2012 дата публикации

Oxygen linked pyrimidine derivatives

Номер: US20120196855A1
Автор: Anders Poulsen, Anthony Deodaunia William, Cheng Hsia Angeline Lee, Eric T. Sun, Harish Kumar Mysore Nagaraj, Stéphanie Blanchard, Yee Ling Evelyn Tan
Принадлежит: SBio Pte Ltd

The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.

Подробнее
Номер записи: 69
02-08-2012 дата публикации

Deferacirox dispersible tablets

Номер: US20120196909A1
Автор: Jean-Pierre Cassiere, Karine Deffez
Принадлежит: NOVARTIS AG

The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet.

Подробнее
Номер записи: 70
09-08-2012 дата публикации

Method

Номер: US20120201864A1
Автор: Christopher J. Rickard, James D. Morrison, Maurice S. Newton, Nigel P. Rhodes, Richard J. Applewhite
Принадлежит: Cytochroma Development Inc

There is provided a method of producing a mixed metal compound comprising at least Mg 2+ and at least Fe + having an aluminium content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 A) comprising the steps of: (a) combining a Mg 2+ salt and a Fe 3+ salt with Na 2 CO 3 and NaOH to produce a slurry, wherein the pH of the slurry is maintained at from 9 5 to 1 1, and wherein the Na 2 CO 3 is provided at an excess of 0 to 4.0 moles than is required to complete the reaction (b) subjecting the slurry to mixing under conditions providing a power per unit volume of 0 03 to 1.6 kW/m 3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product either by (i) heating the crude product to a temperature of no greater than 150° C. and sufficient to provide a water evaporation rate of 0.05 to 1 5 kg water per hour per kg of dry product, or (H) exposing the crude product to rapid drying at a water evaporation rate of 500 to 50000 kg water per hour per kg of dry product.

Подробнее
Номер записи: 71
09-08-2012 дата публикации

Polymorphic forms of deferasirox (icl670a)

Номер: US20120203007A1
Автор: Michael Mutz
Принадлежит: NOVARTIS AG

The invention relates to crystalline forms of 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid and to its amorphous form, to processes for the preparation thereof, to compositions containing the same and their uses for the manufacture of a medicament for the treatment of the human body.

Подробнее
Номер записи: 72
23-08-2012 дата публикации

mTOR/JAK INHIBITOR COMBINATION THERAPY

Номер: US20120214825A1
Автор: Alessandro M. Vannucchi, Costanza BOGANI, Paola Guglielmelli
Принадлежит: Incyte Corp, NOVARTIS PHARMA AG

Provided herein is a combination therapy comprising an mTOR inhibitor and a JAK inhibitor. The combination therapy is useful for the treatment of a variety of cancers, including MPNs. The combination therapy is also useful for the treatment of any number of JAK-associated diseases.

Подробнее
Номер записи: 73
23-08-2012 дата публикации

Specific salt, anhydrous and crystalline form of a dihydropteridione derivative

Номер: US20120214995A1
Автор: Guenter Linz, Matthias Grauert, Peter Sieger, Rolf Schmid
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to a specific salt of a dihydropteridione derivative, namely the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to its crystallisation in the form of an hydrate with water, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.

Подробнее
Номер записи: 74
06-09-2012 дата публикации

Methods of Selective Removal of Products from an Algal Biomass

Номер: US20120223013A1
Автор: Aniket Kale
Принадлежит: Heliae Development LLC

Methods for selective extraction and fractionation of algal lipids and algal products are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which enable efficient separation of algal components. Among these components are neutral lipids synthesized by algae, which are extracted by the methods disclosed herein for the production of renewable fuels.

Подробнее
Номер записи: 75
13-09-2012 дата публикации

Methods of Treating or Preventing Autoimmune Diseases With 2,4-Pyrimidinediamine Compounds

Номер: US20120230984A1
Автор: Ankush Argade, Catherine Sylvain, Donald G. Payan, Holger Keim, HUI Li, Jeffrey Clough, Rajinder Singh, Somasekhar Bhamidipati
Принадлежит: Rigel Pharmaceuticals Inc

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

Подробнее
Номер записи: 76
13-09-2012 дата публикации

Anti-vegf monoclonal antibody and pharmaceutical composition comprising said antibody

Номер: US20120231011A1
Автор: Fanxin Ma, Guoliang Yu, Pierre Li, Weimin Zhu, Xin Fan, Yaohuang Ke, Yongke Zhang
Принадлежит: Apexigen Inc, Jiangsu Simcere Pharmaceutical R&D Co Ltd

The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.

Подробнее
Номер записи: 77
13-09-2012 дата публикации

Cysteine variants of interleukin-11 and methods of use thereof

Номер: US20120231040A1
Автор: George N. Cox, Iii
Принадлежит: Bolder Biotechnology Inc

Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.

Подробнее
Номер записи: 78
20-09-2012 дата публикации

Mesenchymal stem cell and the method of use thereof

Номер: US20120237487A1
Автор: Kazuo Hashi, Osamu Honmou, Teiji Uede
Принадлежит: NC MEDICAL RES Inc

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.

Подробнее
Номер записи: 79
20-09-2012 дата публикации

Antibody Substituting for Function of Blood Coagulation Factor VIII

Номер: US20120237517A1
Автор: Hiroyuki Saito, Kunihiro Hattori, Taro Miyazaki, Tetsuhiro Soeda, Tetsuo Kojima
Принадлежит: Chugai Pharmaceutical Co Ltd

The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.

Подробнее
Номер записи: 80
20-09-2012 дата публикации

In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives

Номер: US20120237629A1
Автор: Damien Sha-Tshibey Tshibangu, Francis Oluwole Shode, James Dama Habila, Neil Koorbanally, Opeoluwa Oyehan Oyedeji, Pius Tshimankinda Mpiana
Принадлежит: University of Kwazulu Natal

The invention provides triterpenoid compounds selected from betulinic acid, maslinic acid, oleanolic acid, esters thereof and mixtures of any two or more thereof for the treatment of sickle-cell anaemia.

Подробнее
Номер записи: 81
20-09-2012 дата публикации

Novel Method for Producing Differentiated Cells

Номер: US20120238023A1
Автор: Hiromitsu Nakauchi, Koji Eto, Naoya Takayama, Sou Nakamura
Принадлежит: Individual

The present invention has an object of providing a method for producing specific cells by amplifying cells in a desired differentiation stage. The present invention provides a method for producing specific cells by inducing differentiation of cells, wherein an oncogene is forcibly expressed in cells in a desired differentiation stage to amplify the cells in the desired differentiation stage. The present invention also provides a method for producing specific cells, wherein oncogene-induced senescence (OIS) which is induced by the oncogene expressed in the cells in the desired differentiation stage is suppressed.

Подробнее
Номер записи: 82
27-09-2012 дата публикации

Polymer factor viii moiety conjugates

Номер: US20120244597A1
Автор: Mary J. Bossard, Michael D. Bentley, Ping Zhang
Принадлежит: Nektar Therapeutics

Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.

Подробнее
Номер записи: 83
27-09-2012 дата публикации

Nicotinic acid compositions for treating hyperlipidemia and related methods therefor

Номер: US20120245207A1
Автор: David J. Bova
Принадлежит: Individual

An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.

Подробнее
Номер записи: 84
04-10-2012 дата публикации

Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same

Номер: US20120253008A1
Автор: Carlo Boutton, Hilde Adi Pierrette Revets, Peter Verheesen, Stephanie Staelens
Принадлежит: Ablynx NV

The present invention relates to amino acid sequences that are capable of binding to serum proteins; to compounds, proteins, polypeptides, fusion proteins or constructs comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs; and to uses of such amino acid sequences, compounds, proteins, polypeptides, fusion proteins or constructs.

Подробнее
Номер записи: 85
11-10-2012 дата публикации

Isotonic beverage with chelates

Номер: US20120258087A1
Автор: Gertruda Biruś-Marszałek, Justyna Widłak-Kargul, Marcin Jedlinski, Piotr Kula, Rafał Jedliński
Принадлежит: OLIMP LABS SP z oo

The subject of the invention is an isotonic beverage with chelates containing carbohydrates, mineral amino acid chelates, L-carnitine, sweeteners, flavouring substances, and a diluent, the essential feature of the beverage being the content of up to 0.1 wt % of mineral components in the form of mineral amino acid chelates, preferably bisglycinates and glycinates, from 0.1 to 50 wt % of isomaltulose, up to 15 wt % of L-carnitine and/or its derivatives, from 5 to 84% of carbohydrates, up to 50 wt % of bioactive substances, up to 50 wt % of flavouring substances, up to 80 wt % of polyalcohols, diluents, tableting aids, stabilizers, antioxidants, dyes, and 0.013-25 wt % of sweeteners, whereby its osmolarity is 275-295 mOsm/kg and pH is 2-5.

Подробнее
Номер записи: 86
11-10-2012 дата публикации

4-amino-1,3-thiazine or oxazine derivative

Номер: US20120258961A1
Автор: Shinji Suzuki, Yuuji Kooriyama
Принадлежит: Shionogi and Co Ltd

The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, ring A, Y and the dotted line are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.

Подробнее
Номер записи: 87
18-10-2012 дата публикации

Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors

Номер: US20120264736A1
Автор: Chad E. Bennett, Chad E. Knutson, David J. Cole, Dmitri A. Pissarnitski, Duane A. Burnett, Haiqun Tang, Hongmei Li, Hubert B. Josien, Jing Su, John W. Clader, Li Qiang, Mark D. Mcbriar, Martin S. Domalski, Mary Ann Caplen, Murali Rajagopalan, Ruo Xu, Thavalakulamgara K. Sasikumar, Theodros Asberom, Thomas A. Bara, Wen-Lian Wu, Zhiqiang Zhao
Принадлежит: Schering Corp

This invention discloses novel gamma secretase inhibitors of the formula: R 2 and R 3 , or R 2 and R 4 , or R 3 and R 4 , together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

Подробнее
Номер записи: 88
18-10-2012 дата публикации

Reversible platelet inhibition

Номер: US20120264815A1
Автор: Bruce A. Sullenger, Nanette Que-Gewirth, Sabah Oney, Shahid Nimjee
Принадлежит: Duke University

The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.

Подробнее
Номер записи: 89
25-10-2012 дата публикации

Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas

Номер: US20120270781A1
Автор: Kari Alitalo, Marc G. Achen, Steven Alan Stacker
Принадлежит: Vegenics Pty Ltd

This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.

Подробнее
Номер записи: 90
01-11-2012 дата публикации

Modulation of signal transducer and activator of transcription 3 (stat3)expression

Номер: US20120277284A1
Автор: Eric E. Swayze, Robert A. MacLeod, Susan M. Freier, Youngsoo Kim
Принадлежит: ISIS PHARMACEUTICALS INC

Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.

Подробнее
Номер записи: 91
08-11-2012 дата публикации

Phosphate-binding magnesium salts and uses thereof

Номер: US20120282352A1
Автор: Charles E. Day, Robert L. Lewis
Принадлежит: Cypress Pharmaceuticals Inc

The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.

Подробнее
Номер записи: 92
08-11-2012 дата публикации

Na-k pump modulation

Номер: US20120283189A1
Автор: Helge H. Rasmussen
Принадлежит: Individual

The present invention relates to a method of modulating Na + /K + pump activity, the method comprising contacting the Na + /K + pump with an FXYD protein or a fragment or variant thereof wherein glutathionylation of said Na + /K + pump is altered by said FXYD protein.

Подробнее
Номер записи: 93
08-11-2012 дата публикации

Association between 4-benzamide and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing it

Номер: US20120283244A1
Автор: Aurore Sors, Caryn Trocme-Thibierge, Florence Keime-Guibert
Принадлежит: Laboratoires Servier SAS

Association between 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide of formula (I): or an addition salt thereof with a pharmaceutically acceptable acid or base, and an acetylcholinesterase inhibitor. Medicinal products containing the same which are useful in the treatment of cognitive disturbances associated with cerebral ageing and with neurodegenerative diseases.

Подробнее
Номер записи: 94
08-11-2012 дата публикации

New heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the app metabolism occurs

Номер: US20120283256A1
Автор: Andre Delacourte, Nicolas Lefur, Patricia Melnyk, Stephane Burlet
Принадлежит: Individual

The present invention relates to compounds having the following Formula (I) for use in the prevention and/or the treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs.

Подробнее
Номер записи: 95
15-11-2012 дата публикации

Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer

Номер: US20120288497A1
Автор: David Charles Blakey, Jeffrey Lester Brown, Stephen Charles Emery
Принадлежит: MedImmune Ltd

The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists.

Подробнее
Номер записи: 96
15-11-2012 дата публикации

pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof

Номер: US20120288531A1
Автор: Dana Gelbaum, Dori Pelled, Irina Karmeli, Paul Salama, Shmuel Tuvia
Принадлежит: Individual

The pharmaceutical compositions described comprise a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer for oral delivery. Some pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a ferric compound and at least one bioavailability enhancer (e.g. a salt of a medium chain fatty acid) and a lipophilic medium. The pharmaceutical compositions may be enteric-coated. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed. The methods of treatment described herein increase the level of iron in the bloodstream of a subject by administering to the subject an effective amount of an oral composition of a ferric iron compound.

Подробнее
Номер записи: 97
15-11-2012 дата публикации

Compounds for the treatment of proliferative disorders

Номер: US20120289483A1
Автор: Christopher Borella, HAO LI, Jun Jiang, Keizo Koya, Kevin Foley, Lijun Sun, Mei Zhang, Shoujun Chen, Takayo Inoue, Weiwen Ying, Yaming Wu, Zhenjian Du
Принадлежит: Synta Phamaceuticals Corp

The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein R a , R b , and R 2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.

Подробнее
Номер записи: 98
29-11-2012 дата публикации

Composition for improving blood circulation, containing extract of lindera obtusiloba as active ingredient

Номер: US20120301562A1
Автор: Jee Woong Lim, Jong-Hoon Kim, Jung-Duk Sohn, Jung-Ok Lee, Min-Ho Oak, Seung-Woo Lee, So-Hee Kang, Yongho Na, Youna Oh
Принадлежит: Han Wha Pharma Co Ltd, Yang Ji Chemical Co Ltd

Provided is a composition for improving blood circulation, comprising an extract of Lindera obtusiloba as an active ingredient, and more specifically, to a pharmaceutical composition and a health functional food for preventing and treating thrombotic disorders by improving blood circulation, comprising an extract of Lindera obtusiloba as an active ingredient. The extract of Lindera obtusiloba of the present invention and a crude purified product thereof can be obtained through extraction using various solvents such as water, ethanol, methanol, butanol, etc. Since the extract and the crude purified product have not only excellent inhibitory effect on platelet aggregation induced by various aggregation inductions in vitro, but also excellent inhibitory effect on rapid thrombus formation in vivo, they can be useful for preventing and treating diseases caused by blood circulation disorders such as thromboembolism, etc.

Подробнее
Номер записи: 99
13-12-2012 дата публикации

Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions

Номер: US20120315338A1
Автор: Feng Li, Shi-Jiang Lu
Принадлежит: Stem Cell and Regenerative Medicine International Inc

The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion.

Подробнее
Номер записи: 100